Company news
Halberd Corp. (OTC:HALB) news
Halberd Corp. news releases on 6ix. Latest, Jun 18, 2026: Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring
Press releases & updates
Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring
June 18, 2026
Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
November 3, 2025
Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform
October 27, 2025
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
September 29, 2025
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
May 28, 2025
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
March 17, 2025
Halberd Update on WatchDawg® PTSD Treatment
December 1, 2024
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
September 30, 2024
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
September 10, 2024
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 8, 2024
Halberd Corp. Issues Letter to Shareholders
August 25, 2024
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
July 23, 2024
Halberd/Athena GTX Research Promises a Much Brighter Future
May 21, 2024
Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill
May 8, 2024
Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
April 29, 2024
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
April 3, 2024
Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing
February 7, 2024
Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast"
February 5, 2024
Halberd Corporation 2023 Year-End CEO Update and 2024 Goals
January 10, 2024
CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
January 9, 2024
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
January 8, 2024
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
December 12, 2023
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
November 14, 2023
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp, Featured on The Street Reports Podcast
October 9, 2023
Halberd's Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)
October 3, 2023
Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
September 19, 2023
Astounding Early Test Results of Halberd's Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)
September 5, 2023
Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
August 21, 2023
Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses
August 13, 2023
Halberd Corporation 2Q23 CEO Letter
July 19, 2023
Halberd CEO Mid-Quarter Update
May 30, 2023
Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete
May 22, 2023
Halberd Pre-Clinical Test Protocol Approved
May 8, 2023
Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
May 1, 2023
Halberd Corporation 1Q23 CEO Letter
April 24, 2023
HALB CEO, CTO and YSU's Dr. Sturrus Discuss CDC, Research Discoveries etc., on "The Street Reports Podcasts" Listen Now!
April 19, 2023
Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances
April 16, 2023
Halberd Begins Preclinical Testing at Mississippi State University (MSU)
April 10, 2023
Halberd's Successful Meeting with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens
April 2, 2023
Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma
March 29, 2023
Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University
March 20, 2023
Halberd & Centers for Disease Control to Meet Regarding Eradication of Antibiotic Resistant Pathogens
March 13, 2023
Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria
February 20, 2023
Halberd Corporation Announces Breakthrough in Candida auris Treatment
February 12, 2023
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
February 7, 2023
Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma
January 30, 2023
Halberd Agrees to Animal Testing at Mississippi State University
January 23, 2023
Halberd Corporation 2022 Year End CEO Letter and 2023 Goals
January 2, 2023
Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication
December 5, 2022
"The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach. Listen Now!
December 4, 2022